πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,562 results for β€œCancer” Clear

  1. Cemiplimab-Rwlc

    Regeneron UK Limited

    Non-small Cell Lung Cancer Stage III

    phase 2 small molecule active

    1 trial

  2. Ceralasertib

    United Therapeutics Europe Ltd

    Gynaecological Cancers

    phase 2 small molecule active

    1 trial

  3. Cetuximab

    Hoffmann-La Roche

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  4. Cetuximab

    Merck KGaA, Darmstadt, Germany

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  5. ChAdOx1-MVA 5T4 vaccine

    Barinthus Biotherapeutics plc.

    Intermediate Risk Prostate Cancer

    phase 2 mab terminated

    1 trial

  6. ChAdOx1-PCAQ

    Barinthus Biotherapeutics plc.

    Prostate Cancer

    phase 2 mab terminated

    1 trial

  7. Chemotherapy + immunotherapy

    Hunan Province Tumor Hospital

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Chemotherapy+PD-1 inhibitor+8Gy x 3f

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HR+HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  9. Chidamide TabletsοΌ› PD-L1 Inhibitor (as per chosen drug's prescribing information)οΌ›CarboplatinοΌ› Etoposide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  11. Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  12. Cisplatin Accord Healthcare 1 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord Healthcare 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Vulvar cancer

    phase 2 small molecule active

    1 trial

  13. Cisplatin and Doxorubicin

    Chinese University of Hong Kong

    Gastric Cancer Peritoneal Metastases

    phase 2 small molecule active

    1 trial

  14. Clostridium Butyricum Tablets

    The First People's Hospital of Lianyungang

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 2 small molecule active

    1 trial

  15. Colonoscopy with enhanced dye

    Cardiff Oncology

    Colorectal Cancer

    phase 2 other completed

    1 trial

  16. Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)

    United Therapeutics Europe Ltd

    Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Combinations

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  18. Conventional Roux-en-Y Gastrojejunostomy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  19. Cotellic 20 mg film-coated tablets, Ginisortamab

    Ningbo Cancer Hospital

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. Cretostimogene Grenadenorepvec

    CG Oncology

    High-Risk Non-Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  21. Cyproterone acetate 5

    Teva Pharma GmbH

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  22. Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Rilvegostomig

    AstraZeneca AB

    metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  23. Cyramza 10 mg/ml concentrate for solution for infusion, PACLITAXEL AHCL 6 mg/ml, solution Γ  diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer stage IV with metastases

    phase 2 small molecule active

    1 trial

  24. DABRAFENIB , TRAMETINIB

    Disc Medicine

    ANAPLASTIC THYROID CANCER

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources